UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome

Proceedings of the National Academy of Sciences - PNAS, 2011-02, Vol.108 (8), p.3270-3275

2011

Link zum Volltext

Verfügbarkeit prüfen

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

Journal of clinical oncology, 2010-11, Vol.28 (31), p.4722-4729

2010

Link zum Volltext

Verfügbarkeit prüfen

Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy

Nature communications, 2021-01, Vol.12 (1), p.352-352, Article 352

2021

Link zum Volltext

Verfügbarkeit prüfen

Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme

Journal of clinical oncology, 2007-10, Vol.25 (30), p.4722-4729

2007

Link zum Volltext

Verfügbarkeit prüfen

Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling

Nature communications, 2021-03, Vol.12 (1), p.1858-1858, Article 1858

2021

Link zum Volltext

Verfügbarkeit prüfen

The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma

Nature communications, 2018-05, Vol.9 (1), p.2087-11, Article 2087

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma

Clinical cancer research, 2007-02, Vol.13 (4), p.1253-1259

2007

Link zum Volltext

Verfügbarkeit prüfen

Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma

Proceedings of the National Academy of Sciences - PNAS, 2013-01, Vol.110 (1), p.270-275

2013

Link zum Volltext

Verfügbarkeit prüfen

Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity

Nature communications, 2020-01, Vol.11 (1), p.524-524, Article 524

2020

Link zum Volltext

Verfügbarkeit prüfen

EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma

PloS one, 2014-04, Vol.9 (4), p.e94281-e94281

2014

Link zum Volltext

Verfügbarkeit prüfen

Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors

PloS one, 2019-01, Vol.14 (1), p.e0210608

2019

Link zum Volltext

Verfügbarkeit prüfen

2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations

PloS one, 2011-02, Vol.6 (2), p.e16812-e16812

2011

Link zum Volltext

Verfügbarkeit prüfen

Recent Advances in the Treatment of Malignant Astrocytoma

Journal of clinical oncology, 2006-03, Vol.24 (8), p.1253-1265

2006

Link zum Volltext

Verfügbarkeit prüfen

An epidermal growth factor receptor variant III–targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme

Molecular cancer therapeutics, 2009-10, Vol.8 (10), p.2773-2779

2009

Link zum Volltext

Verfügbarkeit prüfen

Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting

Clinical cancer research, 2006-09, Vol.12 (17), p.5064-5073

2006

Link zum Volltext

Verfügbarkeit prüfen

Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas

Clinical cancer research, 2008-11, Vol.14 (21), p.7068-7073

2008

Link zum Volltext

Verfügbarkeit prüfen

Global identification of MLL2-targeted loci reveals MLL2’s role in diverse signaling pathways

Proceedings of the National Academy of Sciences - PNAS, 2012-10, Vol.109 (43), p.17603-17608

2012

Link zum Volltext

Verfügbarkeit prüfen

Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma

Journal for immunotherapy of cancer, 2021-04, Vol.9 (4), p.e002203

2021

Link zum Volltext

Verfügbarkeit prüfen

A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma

PloS one, 2012-02, Vol.7 (2), p.e31046-e31046

2012

Link zum Volltext

Verfügbarkeit prüfen

Induction of the unfolded protein response drives enhanced metabolism and chemoresistance in glioma cells

PloS one, 2013-08, Vol.8 (8), p.e73267

2013

Link zum Volltext

Verfügbarkeit prüfen

Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice

PloS one, 2013-03, Vol.8 (3), p.e59082

2013

Link zum Volltext

Verfügbarkeit prüfen

Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations

Journal for immunotherapy of cancer, 2019-05, Vol.7 (1), p.142-14, Article 142

2019

Link zum Volltext

Verfügbarkeit prüfen

Repurposing Clemastine to Target Glioblastoma Cell Stemness

Cancers, 2023-09, Vol.15 (18), p.4619

2023

Link zum Volltext

Verfügbarkeit prüfen

Recurrent Glioblastoma Treated with Recombinant Poliovirus

The New England journal of medicine, 2018-07, Vol.379 (2), p.150-161

2018

Link zum Volltext

Verfügbarkeit prüfen

Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy

Nature medicine, 2012-12, Vol.18 (12), p.1835-1840

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 714

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(681)
Mit Volltextzugriff
(662)

Publikationsform

Artikel
(711)
Buchkapitel
(3)

Sprache

Englisch
(714)

Erscheinungsjahr

n.n

Thema

Science & Technology
(435)
Humans
(405)
Life Sciences & Biomedicine
(400)
Animals
(283)
Oncology
(257)
Biological And Medical Sciences
(233)
Medical Sciences
(221)
Mice
(192)
Female
(180)
Male
(171)
Pharmacology. Drug Treatments
(118)
Antineoplastic Agents
(110)
Tumors
(107)
Adult
(101)
Neurology
(98)
Neurosciences & Neurology
(97)
Middle Aged
(95)
Mice, Nude
(92)
Tumors Of The Nervous System. Phacomatoses
(85)
Neoplasm Transplantation
(82)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy

Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme

Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling

The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma

Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma

Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma

Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity

EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma

Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors

2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations

Recent Advances in the Treatment of Malignant Astrocytoma

An epidermal growth factor receptor variant III–targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme

Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting

Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas

Global identification of MLL2-targeted loci reveals MLL2’s role in diverse signaling pathways

Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma

A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma

Induction of the unfolded protein response drives enhanced metabolism and chemoresistance in glioma cells

Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice

Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations

Repurposing Clemastine to Target Glioblastoma Cell Stemness

Recurrent Glioblastoma Treated with Recombinant Poliovirus

Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy

Suchergebnisse filtern